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ABSTRACT 
The gut microbiota, the ensemble of microorganisms living in the gastrointestinal tract, and the 
host have a mutualist relationship. Alterations of this delicate equilibrium can lead to changes in 
microbiota composition and/or function leading to the onset of metabolic diseases (e.g., type 2 
diabetes and non-alcoholic fatty liver diseases). The current knowledge of host-microbiota 
interaction, in health and disease, is limited. Here, by using a translational science approach, we 
were able to identify some of the mechanisms underlying the influence of the microbiota on 
impaired glucose and lipid metabolism. Specifically:  
In Paper I, I explored the microbiota-host interaction and its effect on glucose metabolism. 
Particularly, by performing colonization of germ-free mice, I studied the effect on glucose 
metabolism over time. I investigated the different molecular mechanisms underlying the im-
paired metabolic profile induced by the colonization over time. These findings provide funda-
mental information on how to conduct studies on microbiota and metabolic diseases. 
In Paper II, I identified a novel microbially-produced molecule, imidazole propionate, which is 
increased in the portal vein of subjects with type 2 diabetes. I demonstrated causality of this 
molecule in impaired glucose metabolism by administering it in both in-vivo and in-vitro mod-
els. Moreover, I identified molecular targets of imidazole propionate in the insulin signaling 
cascade, specifically on the insulin receptor substrate proteins, and showed that this effect is 
mediated by activation of the mTOR complex. 
In Paper III, I investigated whether the gut microbiota composition and function is altered in 
subjects with non-alcoholic fatty liver disease. In presence of steatosis, I observed a shift in 
microbiota composition characterized by increased abundance of bacteria from the oral cavity, 
ethanol-producing bacteria, and a reduction in butyrate producing bacteria. On a functional 
level, I observed an enrichment in functions related to metabolic functions and production of 
lipopolysaccharides in subjects with steatosis. 
In conclusion, these findings show that the microbiota is an environmental factor that modulates 
metabolic diseases. Understanding the mechanisms underlying microbial impacts on host me-
tabolism will aid in discovery of novel targets for the treatment of metabolic diseases in hu-
mans. 
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